NGeneBio Co

NGeneBio Co Capital Expenditures

The Capital Expenditures (CapEx) of NGeneBio Co (354200.KQ) as of Nov 17, 2026 is -136.37 M KRW. In the previous year, Capital Expenditures (CapEx) was -238.82 M KRW — a change of -42.90% (higher).

Capital Expenditures

-136.37 MKRW

YoY

-42.90%

Last updated:

Capital Expenditures (CapEx) of NGeneBio Co is 2025 -136.37 M KRW. Capital Expenditures (CapEx) of NGeneBio Co was 2024 -238.82 M KRW. It decreases by -42.90% higher compared to the previous year.

The NGeneBio Co Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-947.85 M KRW
Jan 1, 2019
-4.96 B KRW
Jan 1, 2020
-533.89 M KRW
Jan 1, 2021
-3.02 B KRW
Jan 1, 2022
-1.22 B KRW
Jan 1, 2023
-828.12 M KRW
Jan 1, 2024
-238.82 M KRW
Jan 1, 2025
-136.37 M KRW
The NGeneBio Co Capital Expenditures history
YEARCapital ExpendituresYoY
-136.37 MKRW-42.90%
-238.82 MKRW-71.16%
-828.12 MKRW-32.38%
-1.22 BKRW-59.48%
-3.02 BKRW+466.14%
-533.89 MKRW-89.24%
-4.96 BKRW+423.37%
-947.85 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NGeneBio Co Stock analysis

What does NGeneBio Co do? NGeneBio Co., Ltd. generates revenue through the development and sale of diagnostic products for cancer-related genetic testing. The company offers BRCAaccuTest for hereditary breast and ovarian cancer, HEMEaccuTest for blood cancer gene testing including leukemia and lymphoma, and SOLIDaccuTest for solid cancer tissues like lung and colon cancer. Additional products include HLAaccuTest for bone marrow transplantation antigen testing, ONCOaccuPanel for large-capacity solid cancer diagnosis, and HEREDaccuTest for rare disease diagnosis. The firm also provides direct-to-consumer genetic testing and personalized healthcare services, targeting healthcare providers, hospitals, and individual consumers seeking genetic insights. The company's product portfolio serves medical institutions and patients requiring precise genetic diagnostics. HEMEaccuTest specifically addresses blood cancer types such as leukemia and lymphoma, while SOLIDaccuTest covers common solid cancers including lung and stomach cancer. ONCOaccuPanel supports comprehensive solid cancer diagnosis, and HEREDaccuTest caters to rare disease diagnostics. These products are sold to healthcare facilities and offered directly to consumers through DTC services. NGeneBio's revenue streams include sales of diagnostic kits and services, with a focus on cancer-related genetic testing. The BRCAaccuTest, HEMEaccuTest, and SOLIDaccuTest products are central to its business, targeting both clinical and direct consumer markets. Personalized healthcare services complement the product offerings, enhancing customer engagement and recurring revenue opportunities. NGeneBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NGeneBio Co stock

Capital Expenditures (CapEx) of NGeneBio Co is -136.37 M KRW in 2025.

Capital Expenditures (CapEx) of NGeneBio Co changed from -238.82 M KRW to -136.37 M KRW, representing a -42.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) NGeneBio Co since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s NGeneBio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — NGeneBio Co

All Key Metrics — NGeneBio Co